

7.



The EU Framework Programme for Research and Innovation HORIZON 2020

Topics for WP 18-20 (RIA, IA, PCP/PPI and & Prizes)



The EU Framework Programme for Research and Innovation HORIZON 2020

Topics for WP 18-20 (ERA-NETs)



New approach to ERA-NET Cofund in WP 18-20

1. JUSTIFICATION OF UNION INTERVENTION: Support H2020 topics; Relevance and complementarity with ongoing actions; EU Added Value = mobilising sufficient resources
2. BUDGETARY ISSUES AND LEVERAGE EFFECTS:
 - Ex-ante national commitments (more than 1 call) + 20% reserve to mitigate for under-commitments in joint calls
 - Higher leverage of EU funding : 1 to 5 for mature networks
1 to 3 for new networks, use CSAs
3. EXPECTED IMPACTS ON EU AND NATIONAL LEVEL:
 - Impact at EU level
 - Impacts at national level

ERA-NET Cofund actions in H2020, SC1, WP 14-15

Overall investment by Member States: More than 250 M€, 7 actions

ERA-NET Cofund	TOTAL INVESTMENT in JOINT CALLS (MS+EC)
E-RARE 3 Rare Diseases Runs from ('15-'19)	17 Countries (19.5 + 5.8 + ~30 Additional Own calls) ~50 M€ (48M€ - 95 % done)
JP cofund, Neurodegenerative diseases ('15-'19)	20 Countries (35 + 10 ? + ? additional) > 40 M€ (46 M€ done, more to do)
TransCan2 Translational Cancer ('15-'19)	19 Countries (17 + 6.7 + ~30 Additional Own calls) ~50 M€ (47 M€ - 95% done)
ERACo-Sysmed System Biology Medicine ('15-'19)	13 Countries (10 + 4 + Additional Own calls?) > 15 M€ (21 M€ --> More to do)
ERA-NET NEURON Brain diseases ('16-'20)	17 Countries (17 + 6.8 + ~40 Additional Own calls) ~60 M€ (40 M€ - 66% done)
ERA-NET JPI Anti-Microbial resistance ('16-'20)	18 Countries (21 + 7.8 + Additional Own calls?) > 26.4 (43 M€ done +more todo)
ERA-CVD Cardiovascular Runs from ('16-'20)	18 Countries (11.4 + 2.5 + Additional Own calls?) ~20 M€ (14M€ --> More to do)
Total Investment in Joint Calls	7 ERA-NET Cofund > 120 M€ + 48 M€ from EC + 100 Own > 250 M€

ERA-NET Cofund actions in H2020, SC1, WP 16-20

Requirements WP 16-17: $\geq 10\text{m€}$ by a critical mass of Member States (10)
 WP 18-20: $\geq 12\text{m€}$, leverage of 3 or 5, ≥ 10 Member States



Title of the suggested topic	MS COMMITMENTS in JOINT CALLS (M€) @ Dec 2016
HCO 3 2017: ERA-NET To implement Strategic Research Agenda on Personalised Medicine	14 countries with commitment, 10 countries supporting, ~12 M€ Committed
ERA-NET titled 'Building sustainable and resilient health care models'	5 countries with commitment, 9 countries supporting, ~3.5 M€ Committed
ERA-NET on Clinical Trials and Translational Research	10 countries with commitment, 8 countries supporting, ~8 M€ Committed
ERA-NET supporting JPI Neurodegenerative diseases	15 countries with commitment, 10 countries supporting, ~13 M€ Committed

SC1 Investment: a balanced portfolio, innovative solutions

Leveraging investment in various type of instruments (Mio€, 2014 to 2017)



WORK IN PROGRESS



- PPP = Public-Private Partnership (IMI-2) = ~ 24% to date, +100% from industry
- P2Ps = (JPIs, Art.185, ERA-NETs, EJP) = ~14% to date, + at least 100 % by partners
- SME Instrument and Financial Instruments (FTI, EFSI, InnovFin ID) = ~7% to date
- Rest of Work Programme = 49 % to date